ASCO 2010 Intro
Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting.
Advancing quality through innovation
Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting.
GI cancer specialists
Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute
Renal cell carcinoma experts
Andrew J. Armstrong, MD, MSc, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK
Hematologic malignancy authority
Samuel M. Silver, MD, PhD, University of Michigan
Our coverage will include the most clinically relevant educational seminars, on-site sessions, abstracts, and breaking news. Please stay tuned over the next several weeks for the best of this year’s exciting meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
